

**PATENT APPLICATION FEE DETERMINATION RECORD**

Substitute for Form PTO-875

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Application or Docket Number**

**CLAIMS AS FILED - PART I**

(Column 1) (Column 2)

If the difference in column 1 is less than zero, enter '0' in column 2.

**CLAIMS AS AMENDED - PART II**

(Column 1)	(Column 2)	(Column 3)	(Column 4)	CHARGE ENTITY	CHARGE ENTITY	OTHER THAN CHARGE ENTITY	
AMENDMENT A	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESERVE EXTRA	RATE	ADDI TIONAL FEE	RATE	ADDI TIONAL FEE
Total EXCHANGES	8	Minus	2	\$ 25		\$ 50	
Independent EXCHANGES	2	Minus	4	\$ 100		200	
				\$ 1		\$ 1	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS (17 CFR 1.10(d))				TOTAL ADDITIONAL FEE		TOTAL ADDITIONAL FEE	

THE INFLUENCE OF SOCIOCULTURAL DIVERSITY AND CULTURAL

COSTS		COSTS		COSTS	
ITEM	DESCRIPTION	ITEM	DESCRIPTION	ITEM	DESCRIPTION
1. GASES	DEDUCT	1. GASES	DEDUCT	1. GASES	DEDUCT
2. WATER	DEDUCT	2. WATER	DEDUCT	2. WATER	DEDUCT
3. WASTE MATERIALS	DEDUCT	3. WASTE MATERIALS	DEDUCT	3. WASTE MATERIALS	DEDUCT
4. EQUIPMENT	DEDUCT	4. EQUIPMENT	DEDUCT	4. EQUIPMENT	DEDUCT
5. OTHER	DEDUCT	5. OTHER	DEDUCT	5. OTHER	DEDUCT
TOTAL		TOTAL		TOTAL	
ADDITIONAL		ADDITIONAL		ADDITIONAL	

Journal of Geometric Morphology, Paper 11, 2019, 1–16. © The Author(s) 2019. This article is published online in advance of print.

© The Royal Society of Chemistry and the Royal Society of Medicine 2006. [www.rsc.org](http://www.rsc.org) RSC member journals

<sup>1</sup> The original version of this paper was presented at the 1997 Annual Meeting of the American Economic Association.

The following table lists the top ten highest-rated books in the appropriate categories.

Patent No. 6,000,000 contains a broad claim directed to the use of the compound of the present invention in the treatment of a disease or condition characterized by the presence of a protein kinase C inhibitor.